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Abstract
Aim To assess cholesterol screening of children with Type 1 diabetes by diabetes professionals using a survey of current
practice, given that National Institute of Health and Care Excellence guidelines on childhood Type 1 diabetes do not
recommend cholesterol screening, yet the National Paediatric Diabetes Audit has an annual cholesterol measure
(> 12 years) as a key outcome indicator.
Methods An online survey was sent to 280 members of the Association of Children’s Diabetes Clinicians to assess
cholesterol screening practice in children.
Results A total of 87 diabetes professionals (31%) responded. The results showed that 94% of respondents measured
cholesterol, 33% did this annually on all children, and 7% measured fasting cholesterol. A total of 63% used no
guidelines to decide treatment or further investigation. The definition of ‘high’ cholesterol varied from > 4.5 to
> 8 mmol/l, with 40% giving no response or specific level. Only 14% of clinicians had started statin therapy in their
diabetes clinic in the previous 5 years.
Conclusion Whilst the majority of diabetes professionals measured cholesterol in children with Type 1 diabetes, there
was marked variability in sampling, in children screened and in action taken if levels were considered abnormal. It is
debatable whether cholesterol measures should be undertaken, certainly more than once, and whether cholesterol level
should feature as a key outcome in the national audit in future.
Diabet. Med. 34, 983–986 (2017)
Introduction
Screening for diabetes complications and associated condi-
tions forms part of the annual clinical review for Type 1
diabetes in childhood and adolescence. The UK National
Institute for Health and Care Excellence (NICE) guidelines
for the management of children and young people with
diabetes (NG18), 2015 [1] do not include cholesterol
screening. In adults, screening for hypercholesterolaemia in
both Type 1 and Type 2 diabetes is recommended on an
annual basis to reduce the risk of associated cardiovascular
complications [2]. In the paediatric population, there is
limited evidence to support routine cholesterol screening.
One systematic review suggests cholesterol testing at
diagnosis and, if normal, then again during puberty [3], but
others oppose cholesterol screening routinely in children,
stating concerns that a high result could be psychologically
damaging and that there is a lack of evidence that treatment
would reduce cardiovascular risk in the long term [4].
Annual cholesterol measurement for children aged
> 12 years, however, forms one of the seven core care
processes outlined in the National Paediatric Diabetes Audit
(NPDA) [5]. In the 2014–2015 audit, 60.8% of children aged
> 12 years underwent a cholesterol measurement. Thus,
there appears to be a disconnect between national guidance
for cholesterol screening and audit requirement, which is
unhelpful for clinical practice. We aimed to assess cholesterol
screening amongst diabetes professionals using a survey of
current practice.
Methods
Members of the Association of Children’s Diabetes Clini-
cians were contacted by email and asked to complete a
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questionnaire via the website Survey Monkey. Members of
the association include consultants, registrars and clinical
nurse specialists based in the UK. The survey asked members
about their use of cholesterol screening (the survey questions
are provided in Table S1). Permission for distribution was
kindly agreed and subsequently circulated by the chair of the
Association. In total, 280 members were emailed in Novem-
ber 2015, and a further reminder email was sent in January
2016.
Results
Of the 280 members emailed, we received 87 responses, a
response rate of 31%. Of those who responded to the survey,
94% measured cholesterol. With regard to the method of
testing, 7% used fasting samples routinely, 17% used fasting
samples only if the random measurement was high, and 41%
used only non-fasting samples (Fig. 1). Some professionals
used a range of measurements in practice; 26.4% used a
fasting sample only if the random measurement was high,
otherwise they used a non-fasting sample, while 1.1% used
either fasting or non-fasting samples.
A total of 33% of professionals measured cholesterol levels
on all children (i.e. those aged > 12 years and those aged
< 12 years) every year, with 40% using annual measure-
ments only in the > 12-year-old population.
In addition to total cholesterol, 67% also measured
triglycerides, HDL and LDL cholesterol levels, 9.2% mea-
sured only triglycerides in addition, while others also
measured a combination of triglycerides and HDL choles-
terol (6.9%), triglycerides and LDL cholesterol (3.4%) or
HDL and LDL cholesterol (3.4%). A total of 9.2% solely
measured cholesterol.
A total of 63% of professionals did not use any guidelines
to decide treatment or further investigation, compared with
29% who did (8% provided no answer). Guidelines used
included: NICE guidelines (24%), International Society for
Paediatric and Adolescent Diabetes (ISPAD; 24%), local
guidelines (16%), ‘Simon Broome criteria’ (8%), American
Diabetes Association (8%), American Academy of Pediatrics
(4%), American Heart Association (4%), British Heart
Foundation (4%) and other (8%).
The reported level of total cholesterol and LDL that would
prompt further action varied. For those who stated they did
not use a guideline, responses relating to total cholesterol
level ranged from no response (24%), no specific level
(16%), and levels > 4.5 mmol/l (3.6%), > 5 mmol/l (22%),
> 5.5 mmol/l (7.3%), > 6 mmol/l (12.7%), 6.7 mmol/l
(3.6%), > 7 mmol/l (9%) and > 8 mmol/l (1.8%). Action
after observing an above-threshold cholesterol level included
referral to a dietician (42% of respondents), referral to a
lipidologist (14%) and commencement of a statin (2%). A
total of 16% of respondents would refer to a dietician and
lipidologist, 10% would refer to a dietician and commence a
statin, 3% would refer to a lipidologist, dietician and
commence a statin, and 13% of professionals would not
take any further action.
Only 14% of clinicians reported that a child with diabetes
was started on statins in their clinic in the previous 5 years,
with the number of cases reported per clinician varying
between one and six children (median = 2). The number of
children reported to have had high LDL or total cholesterol
levels varied from 0 to 50 children per clinician
(median = 0).
Discussion
Despite annual screening for cholesterol not being included
in NICE guidelines, 94% of clinicians surveyed measured
FIGURE 1 Means of cholesterol measurement in children with Type 1
diabetes.
What’s new?
• Annual measurement of cholesterol in children aged
> 12 years with Type 1 diabetes is one of the seven core
care processes outlined in the National Paediatric
Diabetes Audit (NPDA).
• The National Institute for Health and Care Excellence
(NICE) guidelines (NG18) for management of children
and young people with diabetes 2015, do not include
cholesterol screening for children with Type 1 diabetes.
• There is much variation in cholesterol measurement,
evaluation and treatment among clinicians looking
after children with Type 1 diabetes.
• We suggest further evidence is needed on the utility of
cholesterol screening in the paediatric population, and
consistency is needed between NICE guidance and
NPDA standards.
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cholesterol routinely, probably largely because such screen-
ing is included in the NPDA ‘essential’ seven care processes.
Only a minority (6%) followed NICE guidance and did not
routinely measure cholesterol. Furthermore, amongst clini-
cians who measured cholesterol, there was much variation in
practice regarding who was screened and which test was
used.
Evidence to support the screening of cholesterol in the
paediatric population is limited. An analysis of three systemic
reviews concluded that practice may include measuring lipids
6 months after diagnosis and, if normal, then again in
puberty [3]. Even compared with this more proactive
approach, a third of clinicians would be considered to be
over-investigating for dyslipidaemia by testing in all age
groups annually.
The SEARCH for Diabetes in Youth case–control study
showed that, in young people with Type 1 diabetes, even
with a short disease duration, glycaemic control influenced
lipid profiles [6]. Those with optimum diabetes control
(defined as HbA1c 58 mmol/mol or < 7.5%) had similar
lipid profiles to those of young people without diabetes.
Those with suboptimum control (defined as HbA1c
> 58 mmol/mol or > 7.5%) had a higher prevalence of
lipid abnormalities compared with the control group. A key
issue for national policy-makers when deciding on advice
about screening for hypercholesterolaemia is the lack of
randomized controlled trials in children and young people.
The results of the AdDIT trial [7], which randomized
children with Type 1 diabetes and microalbuminura to
receive either an angiotensin-converting enzyme inhibitor, a
statin, combination therapy or placebo for 3–4 years, may
help inform the debate on the efficacy and safety of statin
treatment in this age group. Although the primary outcome
was improvement in microalbuminuria, secondary out-
comes included measures of cardiovascular health and lipid
profiles.
The perceived level of abnormality of cholesterol varied
from levels > 4.5 mmol/l to > 8 mmol/l, with many profes-
sionals unsure of the level considered abnormal. This lack of
consensus amongst professionals means there is wide varia-
tion in the level that would trigger further investigations,
referral to other professionals and treatment. The lack of
clarity on acceptable lipid limits and what is the appropriate
treatment is not unique to the UK, being seen internationally
with a wide range of thresholds across multiple international
guidelines [8]. The two most popular guidelines used by
professionals were the ISPAD consensus guideline where an
elevated LDL cholesterol level is defined as ≥ 2.6 mmol/l
(100 mg/dl) and NICE Familial Hypercholesterolaemia
guideline (CG71), where a total cholesterol concentration
of > 7.5 mmol/l is cause for further investigation and
possible treatment.
A response rate of 31%, leaves 69% of the membership of
the professional body whose views are not reflected in the
present results. The views and practice of 87 professionals
working with young people across the UK remains a useful
barometer to understand practice, but may not be indicative
of precise treatment at the individual patient level. However,
as 61% of children aged > 12 years had their cholesterol
measured, according to the last NPDA report [5], the present
findings suggest it is still a part of many professionals’ clinical
practice. A more robust assessment of cholesterol manage-
ment would be to collect national data on actual levels of
screening (already carried out in the NPDA), the number of
statin prescriptions issued and referrals to dieticians and
lipidologists. This is beyond the scope of the present study,
but could form the basis of future work as part of a later
NPDA survey.
The cost implications of routine cholesterol screening
across the National Health Service is significant, given that
there are currently 26 364 under 19-year-olds with Type 1
diabetes in the UK [5]. Considering the cost of indiscriminate
annual screening, and the low yield of abnormal results from
this process, a more measured and targeted approach is
indicated.
Further research into the use of cholesterol screening in the
paediatric population is needed, including assessing any
impact on long-term cardiovascular health. With such
variation in the guidance used and in what is considered an
abnormal cholesterol result, it is imperative that clinicians
have agreed national guidance for managing hypercholes-
terolaemia in childhood Type 1 diabetes. Certainly, some
clarity is needed for clinicians, with some continuity
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Survey questions.
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